Key result
Simvastatin /day for 3 months increased flow-mediated dilation from 6.12% to 10.32% and reduced hs-CRP levels by 51.6% in children with Kawasaki disease and coronary abnormalities.
Why the study?
Does simvastatin improve chronic vascular inflammation and endothelial dysfunction in children complicated with coronary arterial abnormality late after Kawasaki disease?
Does simvastatin improve chronic vascular inflammation and endothelial dysfunction in children complicated with coronary arterial abnormality late after Kawasaki disease?
Short-term simvastatin therapy significantly improves chronic vascular inflammation and endothelial dysfunction in children with coronary arterial abnormalities late after Kawasaki disease.
Answers are grounded in this paper and cite their sources.
May support simvastatin for endothelial function in post-Kawasaki children with coronary abnormalities; hypothesis-generating, needs randomized confirmation.
BACKGROUND: Ongoing low-grade inflammation and endothelial dysfunction persist in patients late after Kawasaki disease (KD). Statins not only reduce cholesterol, but also improve surrogate markers of atherosclerosis and endothelial dysfunction, but their effects for children late after KD complicated with coronary arterial abnormality (CAA) has not been evaluated. METHODS AND RESULTS: The 11 KD children complicated with CAA (mean age 12.9+/-2.5 years, mean interval from episode 10.77+/-3.01 years) and 11 age- and gender-matched healthy controls were studied. The KD group received oral simvastatin 10 mg/day for 3 months. Lipid profiles, high-sensitivity C-reactive protein (hs-CRP) and flow-mediated dilation (FMD) of the brachial artery were performed at baseline in both groups and 3 months later in the KD group. At baseline, the KD group had significantly higher hs-CRP level and decreased FMD than the control group. After 3 months' treatment, the KD group showed a significant reduction in the hs-CRP level and a significant increase in FMD. CONCLUSIONS: In this small study, short-term statin therapy appeared to significantly improve chronic vascular inflammation and endothelial dysfunction with no adverse effects in children complicated by CAA late after KD. However, long-term and randomized studies are still needed to make further conclusions.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2008) studied Kawasaki disease complicated with coronary arterial abnormality (n=22). Simvastatin vs. Baseline (pre-treatment) was evaluated on Flow-mediated dilation (FMD) of the brachial artery (p=<0.001). Simvastatin /day for 3 months increased flow-mediated dilation from 6.12% to 10.32% and reduced hs-CRP levels by 51.6% in children with Kawasaki disease and coronary abnormalities.
Synapse has enriched 10 related papers. Consider them for comparative context: